Exact Mass: 401.279061

Exact Mass Matches: 401.279061

Found 305 metabolites which its exact mass value is equals to given mass value 401.279061, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Myriocin

(2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid;ISP-I;Thermozymocidin

C21H39NO6 (401.2777234)


An amino acid-based antibiotic derived from certain thermophilic fungi; acts as a potent inhibitor of serine palmitoyltransferase, the first step in sphingosine biosynthesis. Myriocin also possesses immunosuppressant activity. D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents [Raw Data] CBA29_Myriocin_pos_20eV_1-3_01_1557.txt [Raw Data] CBA29_Myriocin_neg_40eV_1-3_01_1590.txt [Raw Data] CBA29_Myriocin_pos_10eV_1-3_01_1546.txt [Raw Data] CBA29_Myriocin_neg_30eV_1-3_01_1589.txt [Raw Data] CBA29_Myriocin_pos_40eV_1-3_01_1559.txt [Raw Data] CBA29_Myriocin_pos_30eV_1-3_01_1558.txt [Raw Data] CBA29_Myriocin_pos_50eV_1-3_01_1560.txt [Raw Data] CBA29_Myriocin_neg_10eV_1-3_01_1578.txt [Raw Data] CBA29_Myriocin_neg_20eV_1-3_01_1588.txt Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].

   

Calpain inhibitor II

N-Acetylleucyl-leucyl-methioninal

C19H35N3O4S (401.2348150000001)


   

6'-Hydroxybuspirone

6-hydroxy-8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione

C21H31N5O3 (401.2426776)


6-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)

   

Buspirone N-oxide

8-{4-[1-oxo-4-(pyrimidin-2-yl)-1λ⁵-piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione

C21H31N5O3 (401.2426776)


Buspirone N-oxide is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)

   

3'-Hydroxybuspirone

2-hydroxy-8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione

C21H31N5O3 (401.2426776)


3-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)

   

5-Hydroxybuspirone

8-{4-[4-(5-hydroxypyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione

C21H31N5O3 (401.2426776)


5-Hydroxybuspirone is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)

   

3-hydroxypentadecanoyl carnitine

3-[(3-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


3-Hydroxypentadecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxypentadecanoyl carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxypentadecanoyl carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

O-(13-Carboxytridecanoyl)carnitine

3-[(13-Carboxytridecanoyl)oxy]-4-(trimethylammonio)butanoic acid

C21H39NO6 (401.2777234)


O-(13-Carboxytridecanoyl)carnitine is an acylcarnitine. More specifically, it is an tetradecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-(13-Carboxytridecanoyl)carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-(13-Carboxytridecanoyl)carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxypentadecanoylcarnitine

3-[(10-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


10-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Hydroxypentadecanoylcarnitine

3-[(7-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


7-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Hydroxypentadecanoylcarnitine

3-[(9-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


9-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxypentadecanoylcarnitine

3-[(6-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


6-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxypentadecanoylcarnitine

3-[(5-hydroxypentadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C22H43NO5 (401.31410680000005)


5-Hydroxypentadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxypentadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxypentadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-Hydroxypentadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Arachidonoyl Proline

1-(icosa-5,8,11,14-tetraenoyl)pyrrolidine-2-carboxylic acid

C25H39NO3 (401.29297840000004)


N-arachidonoyl proline belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Proline. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Proline is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Proline is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Eicosapentaenoyl Valine

2-(icosa-5,8,11,14,17-pentaenamido)-3-methylbutanoic acid

C25H39NO3 (401.29297840000004)


N-eicosapentaenoyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(2S,3R,4R)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid

(2S,3R,4R)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid

C21H39NO6 (401.2777234)


   

5-Methylurapidil

6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3,5-trimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

C21H31N5O3 (401.2426776)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-((4-phenyl-1-piperazinyl)methyl)-s-triazin-2-yl)-

Isoquinoline, 1,2,3,4-tetrahydro-2-(4-amino-6-((4-phenyl-1-piperazinyl)methyl)-s-triazin-2-yl)-

C23H27N7 (401.23278220000003)


   

Anisperimus

({6-[(diaminomethylidene)amino]hexyl}carbamoyl)methyl N-{4-[(3-aminobutyl)amino]butyl}carbamate

C18H39N7O3 (401.31142239999997)


   

Cetilistat

2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one

C25H39NO3 (401.29297840000004)


C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors

   

[2-Amino-2-(hydroxymethyl)-5-(4-octylphenyl)pentyl] dihydrogen phosphate

2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol monodihydrogen phosphate ester

C20H36NO5P (401.23309760000006)


   

N-Allm

2-acetamido-4-methyl-N-(3-methyl-1-{[4-(methylsulfanyl)-1-oxobutan-2-yl]carbamoyl}butyl)pentanamide

C19H35N3O4S (401.2348150000001)


   
   

(+)-Sphingofungin F

(+)-Sphingofungin F

C21H39NO6 (401.2777234)


   
   
   
   
   

(3E,9E)-5-Hydroxy-14-isobutyl-9,12,13-trimethyl-6,7,8,10a,13,13a,14,15-octahydro-2H-oxacyclododecino[2,3-d]isoindole-2,16(5H)-dione

NCGC00347526-02_C24H35NO4_(3E,9E)-5-Hydroxy-14-isobutyl-9,12,13-trimethyl-6,7,8,10a,13,13a,14,15-octahydro-2H-oxacyclododecino[2,3-d]isoindole-2,16(5H)-dione

C24H35NO4 (401.25659500000006)


   
   

SN 198D

(-)-7-Demethylpiericidin A1

C24H35NO4 (401.25659500000006)


   
   
   

Lucidusculine

Luciculine 15-acetate

C24H35NO4 (401.25659500000006)


   

C24H35NO4

NCGC00380312-01_C24H35NO4_

C24H35NO4 (401.25659500000006)


   
   
   

12-epi-15-O-acetylnapelline|12-epi-lucidusculine

12-epi-15-O-acetylnapelline|12-epi-lucidusculine

C24H35NO4 (401.25659500000006)


   
   
   
   

8,21-dehydro-17,20-epoxyeujindole

8,21-dehydro-17,20-epoxyeujindole

C28H35NO (401.27185000000003)


   
   

3(R)-Benzoyloxy-2(R)-methyl-6(R)-(11-oxododecyl)-piperidine

3(R)-Benzoyloxy-2(R)-methyl-6(R)-(11-oxododecyl)-piperidine

C25H39NO3 (401.29297840000004)


   
   

glutaminylvalylarginine

glutaminylvalylarginine

C16H31N7O5 (401.2386556)


   
   
   
   
   
   
   

valylglutaminylarginine

valylglutaminylarginine

C16H31N7O5 (401.2386556)


   
   
   

asparagylisoleucylarginine

asparagylisoleucylarginine

C16H31N7O5 (401.2386556)


   
   
   
   
   
   

C24H35NO4_1H-Cycloundec[d]isoindole-1,15(2H)-dione, 3,3a,4,6a,9,10,11,12-octahydro-11,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (7E,13E)

NCGC00380732-01_C24H35NO4_1H-Cycloundec[d]isoindole-1,15(2H)-dione, 3,3a,4,6a,9,10,11,12-octahydro-11,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (7E,13E)-

C24H35NO4 (401.25659500000006)


   

C25H39NO3_(7E)-3-Isobutyl-13-methoxy-4,5,8-trimethyl-3,3a,4,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione

NCGC00380397-01_C25H39NO3_(7E)-3-Isobutyl-13-methoxy-4,5,8-trimethyl-3,3a,4,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione

C25H39NO3 (401.29297840000004)


   

C24H35NO4_(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-Hydroxy-8-isobutyl-5,6,15-trimethyl-19-oxa-9-azapentacyclo[13.3.1.0~2,14~.0~3,11~.0~7,11~]nonadec-4-ene-10,12-dione

NCGC00386058-01_C24H35NO4_(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-Hydroxy-8-isobutyl-5,6,15-trimethyl-19-oxa-9-azapentacyclo[13.3.1.0~2,14~.0~3,11~.0~7,11~]nonadec-4-ene-10,12-dione

C24H35NO4 (401.25659500000006)


   

6-hydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2H,5H,6H,7H,8H,13H,13aH,14H,15H,16H,16bH-oxacyclododeca[3,2-e]isoindole-2,16-dione

6-hydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-2H,5H,6H,7H,8H,13H,13aH,14H,15H,16H,16bH-oxacyclododeca[3,2-e]isoindole-2,16-dione

C24H35NO4 (401.25659500000006)


   

(Z)-N-hexadec-9-enoyl-L-phenylalanine

(Z)-N-hexadec-9-enoyl-L-phenylalanine

C25H39NO3 (401.29297840000004)


   

Ala Ala Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-methylpentanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Ala Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]-3-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Ala Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]-4-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Ala Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-4-methylpentanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Gly Arg Val

(2S)-2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Ala Gly Val Arg

(2S)-2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Ala Ile Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-aminopropanamido]-3-methylpentanamido]propanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Ile Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-aminopropanamido]-3-methylpentanamido]hexanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Lys Ala Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]-3-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Lys Ala Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]-4-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Lys Ile Ala

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-methylpentanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Lys Leu Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-4-methylpentanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Leu Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-methylpentanamido]propanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Leu Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-methylpentanamido]hexanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ala Arg Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]acetamido}-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Ala Arg Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Ala Val Gly Arg

(2S)-2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]acetamido}-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Ala Val Arg Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

DIDESMETHYL MIFEPRISTONE

N-Didesmethylmifepristone (RU 42848)

C27H31NO2 (401.2354666)


   

Gly Ala Arg Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Gly Ala Val Arg

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

5-Hydroxybuspirone

5-Hydroxy Buspirone

C21H31N5O3 (401.2426776)


   

Gly Gly Ile Arg

(2S)-2-[(2S,3S)-2-[2-(2-aminoacetamido)acetamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Gly Leu Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Gly Arg Ile

(2S,3S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Gly Arg Leu

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Ile Gly Arg

(2S)-2-{2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]acetamido}-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Ile Arg Gly

2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Gly Lys Val Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylbutanamido]-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Gly Leu Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]acetamido}-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Leu Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Ala Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]propanamido]-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Gly Ile

(2S,3S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-3-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Gly Leu

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-4-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Ile Gly

2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-methylpentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Leu Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-4-methylpentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Gly Arg Val Ala

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-methylbutanamido]propanoic acid

C16H31N7O5 (401.2386556)


   

Gly Val Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]propanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Gly Val Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]hexanamido]-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Gly Val Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-5-carbamimidamidopentanamido]propanoic acid

C16H31N7O5 (401.2386556)


   

Gly Val Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-methylbutanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ile Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]propanamido]propanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Ile Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]propanamido]hexanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ile Gly Gly Arg

(2S)-2-(2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Ile Gly Arg Gly

2-[(2S)-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   
   

Ile Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]propanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Ile Arg Gly Gly

2-{2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

C16H31N7O5 (401.2386556)


   

Lys Ala Ala Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]-3-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Ala Ala Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]-4-methylpentanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Ala Ile Ala

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-methylpentanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Ala Leu Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-4-methylpentanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Gly Val Val

(2S)-2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylbutanamido]-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Ile Ala Ala

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]propanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Leu Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]propanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   
   

Lys Val Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]acetamido}-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Lys Val Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-methylbutanamido]acetic acid

C18H35N5O5 (401.26380600000005)


   

Leu Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]propanamido]propanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Leu Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]propanamido]hexanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   
   

Leu Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Leu Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Leu Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]propanamido]propanoic acid

C18H35N5O5 (401.26380600000005)


   

Leu Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

C16H31N7O5 (401.2386556)


   
   
   
   
   
   
   
   
   

Arg Ala Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]acetamido}-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Arg Ala Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]-3-methylbutanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Ala Val

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}propanamido]-3-methylbutanoic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Gly Ile

(2S,3S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-3-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Gly Leu

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-4-methylpentanoic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Ile Gly

2-[(2S,3S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-methylpentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Leu Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-4-methylpentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Arg Gly Val Ala

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-methylbutanamido]propanoic acid

C16H31N7O5 (401.2386556)


   

Arg Ile Gly Gly

2-{2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]acetamido}acetic acid

C16H31N7O5 (401.2386556)


   

Arg Leu Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]acetamido}acetic acid

C16H31N7O5 (401.2386556)


   

Arg Val Ala Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]propanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Arg Val Gly Ala

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]acetamido}propanoic acid

C16H31N7O5 (401.2386556)


   
   
   
   

Val Ala Gly Arg

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]acetamido}-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Val Ala Arg Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]-5-carbamimidamidopentanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Val Gly Ala Arg

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}propanamido]-5-carbamimidamidopentanoic acid

C16H31N7O5 (401.2386556)


   

Val Gly Lys Val

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}hexanamido]-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Val Gly Arg Ala

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-5-carbamimidamidopentanamido]propanoic acid

C16H31N7O5 (401.2386556)


   

Val Gly Val Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-3-methylbutanamido]hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Val Lys Gly Val

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]acetamido}-3-methylbutanoic acid

C18H35N5O5 (401.26380600000005)


   

Val Lys Val Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-methylbutanamido]acetic acid

C18H35N5O5 (401.26380600000005)


   

Val Arg Ala Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]propanamido]acetic acid

C16H31N7O5 (401.2386556)


   

Val Arg Gly Ala

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]acetamido}propanoic acid

C16H31N7O5 (401.2386556)


   

Val Val Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]acetamido}hexanoic acid

C18H35N5O5 (401.26380600000005)


   

Val Val Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]hexanamido]acetic acid

C18H35N5O5 (401.26380600000005)


   

Sphingofungin F

2S-amino-3R,4R,5S-trihydroxy-2-methyl-14-oxo-eicos-6E-enoic acid

C21H39NO6 (401.2777234)


   
   
   

PGF2alpha-EA(d4)

N-(9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl)-ethanolamine(d4)

C22H35D4NO5 (401.30791711200004)


   

CAR 14:1;O2

13-carboxytridecanoylcarnitine;3-[(13-carboxytridecanoyl)oxy]-4-(trimethylammonio)butanoate

C21H39NO6 (401.2777234)


   

4,4,4-tri-tert-butyl-2,2:6,2-terpyridine

4,4,4-tri-tert-butyl-2,2:6,2-terpyridine

C27H35N3 (401.28308300000003)


   
   

1,3-DIIMINO-5,6-BIS(OCTYLOXY)ISOINDOLINE

1,3-DIIMINO-5,6-BIS(OCTYLOXY)ISOINDOLINE

C24H39N3O2 (401.3042114)


   

p-dodecylbenzenesulphonic acid, compound with 1-aminopropan-2-ol (1:1)

p-dodecylbenzenesulphonic acid, compound with 1-aminopropan-2-ol (1:1)

C21H39NO4S (401.25996540000006)


   

(3S,4aS,8aS)-2-[(3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide

(3S,4aS,8aS)-2-[(3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-tert-butyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide

C24H39N3O2 (401.3042114)


   

biperiden lactate

biperiden lactate

C24H35NO4 (401.25659500000006)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

4-Hydroxy-alpha1-[[[6-(3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol

4-Hydroxy-alpha1-[[[6-(3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol

C24H35NO4 (401.25659500000006)


   

ALLM (Calpain Inhibitor)

ALLM (Calpain Inhibitor)

C19H35N3O4S (401.2348150000001)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D007976 - Leupeptins

   

[[1-[N-Hydroxy-acetamidyl]-3-methyl-butyl]-carbonyl-leucinyl]-alanine ethyl ester

[[1-[N-Hydroxy-acetamidyl]-3-methyl-butyl]-carbonyl-leucinyl]-alanine ethyl ester

C19H35N3O6 (401.25257300000004)


   

4-(3,4-dihydro-2H-quinolin-1-yl)-6-[(4-phenyl-1-piperazinyl)methyl]-1,3,5-triazin-2-amine

4-(3,4-dihydro-2H-quinolin-1-yl)-6-[(4-phenyl-1-piperazinyl)methyl]-1,3,5-triazin-2-amine

C23H27N7 (401.23278220000003)


   
   
   
   

Cetilistat

Cetilistat

C25H39NO3 (401.29297840000004)


C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors

   

Dehydrocholate

Dehydrocholate

C24H33O5- (401.23278680000004)


D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

(E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-icos-6-enoic acid

(E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-icos-6-enoic acid

C21H39NO6 (401.2777234)


   
   
   
   
   
   

1-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]pyrrolidine-2-carboxylic acid

1-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]pyrrolidine-2-carboxylic acid

C25H39NO3 (401.29297840000004)


   
   

ALLM

N-Acetylleucyl-leucyl-methioninal

C19H35N3O4S (401.2348150000001)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors

   
   

[1-(3-Phenoxypropyl)-4-piperidinyl]-diphenylmethanol

[1-(3-Phenoxypropyl)-4-piperidinyl]-diphenylmethanol

C27H31NO2 (401.2354666)


   

1-ethyl-4-hydroxy-2-oxo-N-(1-oxodecyl)-3-quinolinecarbohydrazide

1-ethyl-4-hydroxy-2-oxo-N-(1-oxodecyl)-3-quinolinecarbohydrazide

C22H31N3O4 (401.23144460000003)


   

(3E,9E)-5,6-Dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione

(3E,9E)-5,6-Dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione

C24H35NO4 (401.25659500000006)


   

(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-hydroxy-5,6,15-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.02,14.03,11.07,11]nonadec-4-ene-10,12-dione

(1S,2R,3R,6S,7R,8S,11S,14S,15S,18R)-18-hydroxy-5,6,15-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.02,14.03,11.07,11]nonadec-4-ene-10,12-dione

C24H35NO4 (401.25659500000006)


   
   
   
   

asperterpenoid C(1-)

asperterpenoid C(1-)

C25H37O4- (401.2691702)


   

5,6-dimethyl-2-[1-[[1-(phenylmethyl)-5-tetrazolyl]methyl]-4-piperidinyl]-1H-benzimidazole

5,6-dimethyl-2-[1-[[1-(phenylmethyl)-5-tetrazolyl]methyl]-4-piperidinyl]-1H-benzimidazole

C23H27N7 (401.23278220000003)


   

N-cyclopropyl-1-[1-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]-oxomethyl]-4-piperidinyl]-4-piperidinecarboxamide

N-cyclopropyl-1-[1-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]-oxomethyl]-4-piperidinyl]-4-piperidinecarboxamide

C22H35N5O2 (401.279061)


   

1-[2-[[(2,3-dihydro-1H-inden-5-ylamino)-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester

1-[2-[[(2,3-dihydro-1H-inden-5-ylamino)-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester

C22H31N3O4 (401.23144460000003)


   

(9E)-4-Methoxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,18-dione

(9E)-4-Methoxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,18-dione

C25H39NO3 (401.29297840000004)


   
   

Crambescidin 401

Crambescidin 401

C22H31N3O4 (401.23144460000003)


An organic heteropentacyclic guanidine alkaloid isolated from the marine sponge Crambe crambe.

   

(2R,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

2-[(2S,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2S,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2S,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2S,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

(2S,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2S,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C22H31N3O4 (401.23144460000003)


   

2-[(2S,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2S,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2R,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2R,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2R,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2R,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2R,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2R,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2S,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2S,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   

2-[(2R,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

2-[(2R,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide

C22H31N3O4 (401.23144460000003)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]hexadecanoate

16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]hexadecanoate

C22H41O6- (401.2902986)


   

(E,3S,4S)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid

(E,3S,4S)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid

C21H39NO6 (401.2777234)


   

15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate

15-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate

C21H37O7- (401.2539152)


   

15-(3,5-Dihydroxy-6-methyloxan-2-yl)oxyhexadecanoate

15-(3,5-Dihydroxy-6-methyloxan-2-yl)oxyhexadecanoate

C22H41O6- (401.2902986)


   

(14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate

(14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxopentadecanoate

C21H37O7- (401.2539152)


   

(3Z,9Z)-5,6-dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione

(3Z,9Z)-5,6-dihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,18-dione

C24H35NO4 (401.25659500000006)


   
   
   
   
   

O-(13-carboxytridecanoyl)carnitine

O-(13-carboxytridecanoyl)carnitine

C21H39NO6 (401.2777234)


An O-acylcarnitine having 13-carboxytridecanoyl as the acyl substituent.

   
   
   

ascr#28(1-)

ascr#28(1-)

C22H41O6 (401.2902986)


Conjugate base of ascr#28

   

oscr#28(1-)

oscr#28(1-)

C22H41O6 (401.2902986)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#28, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   
   
   
   

Ro 64-6198

Ro 64-6198

C26H31N3O (401.2466996)


Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC50 value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia[1][2].

   

(1'r,2s,2's,4's,8'r,9's,13's,16's,18's)-16'-amino-9',13'-dimethyl-5'-oxaspiro[oxolane-2,7'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-5,6'-dione

(1'r,2s,2's,4's,8'r,9's,13's,16's,18's)-16'-amino-9',13'-dimethyl-5'-oxaspiro[oxolane-2,7'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-5,6'-dione

C24H35NO4 (401.25659500000006)


   

1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO4 (401.25659500000006)


   

(5s,10as,13s,13as,14s,16ar)-5,16-dihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one

(5s,10as,13s,13as,14s,16ar)-5,16-dihydroxy-9,12,13-trimethyl-14-(2-methylpropyl)-5h,6h,7h,8h,10ah,13h,13ah,14h-oxacyclododeca[3,2-d]isoindol-2-one

C24H35NO4 (401.25659500000006)


   

(1r,2s,3s,6r,7s,8r,11s,14r,15r,16s)-10,16-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-dien-12-one

(1r,2s,3s,6r,7s,8r,11s,14r,15r,16s)-10,16-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[13.3.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-dien-12-one

C24H35NO4 (401.25659500000006)


   

(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C24H35NO4 (401.25659500000006)


   

(3s,3ar,4s,6ar,13r,15ar)-1,13-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

(3s,3ar,4s,6ar,13r,15ar)-1,13-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

C24H35NO4 (401.25659500000006)


   

(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-4,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-yl acetate

(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-4,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-yl acetate

C24H35NO4 (401.25659500000006)


   

(3s,3ar,4s,6as,11s,12r,15ar)-1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

(3s,3ar,4s,6as,11s,12r,15ar)-1,11,12-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO4 (401.25659500000006)


   

(1r,5r,8r,10r,11r,12s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-yl acetate

(1r,5r,8r,10r,11r,12s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-yl acetate

C24H35NO4 (401.25659500000006)